Curi RMB Capital LLC Invests $59,000 in Tharimmune, Inc. (NASDAQ:THAR)

Curi RMB Capital LLC bought a new stake in shares of Tharimmune, Inc. (NASDAQ:THAR) in the third quarter, Holdings Channel reports. The fund bought 23,620 shares of the company’s stock, valued at approximately $59,000.

Tharimmune Trading Down 2.7 %

NASDAQ THAR opened at $2.17 on Friday. The stock has a 50-day simple moving average of $2.44 and a two-hundred day simple moving average of $3.35. Tharimmune, Inc. has a fifty-two week low of $1.84 and a fifty-two week high of $79.65.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).